484PD - A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer

Date 21 December 2015
Event ESMO Asia 2015 Congress
Session Basic Science, biomarkers, new diagnostics and translational research
Topics Anti-Cancer Agents & Biologic Therapy
Lung and other Thoracic Tumours
Personalised Medicine
Presenter Eiji Iwama
Citation Annals of Oncology (2015) 26 (suppl_9): 148-152. 10.1093/annonc/mdv533
Authors E. Iwama1, K. Sakai2, K. Azuma3, K. Nosaki4, D. Harada5, K. Hotta6, F. Ohyanagi7, T. Kurata8, H. Akamatsu9, K. Goto10, T. Fukuhara11, Y. Nakanishi1, K. Nishio2, I. Okamoto1
  • 1Research Institute For Disease Of The Chest, Kyushu University, 812-8582 - Fukuoka/JP
  • 2Department Of Genome Biology, Kinki University School of Medicine, 589-8511 - Osakasayama/JP
  • 3Division Of Respirology, Neurology, And Rheumatology, Department Of Internal Medicine, Kurume University School of Medicine, Fukuoka/JP
  • 4Department Of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka/JP
  • 5Department Of Thoracic Oncology, Shikoku Cancer Center, Matsuyama/JP
  • 6Respiratory Medicine, Okayama University Hospital, Okayama/JP
  • 7Department Of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 8First Department Of Internal Medicine, Kansai Medical University, Osaka/JP
  • 9Thirddepartment Of Internal Medicine, Wakayama Medical University, Wakayama/JP
  • 10Thoracic Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 11Department Of Respiratory Medicine, Miyagi Cancer Center, Sendai/JP

Abstract

Aim/Background

Afatinib is an oral, irreversible ErbB family blocker and effective for EGFR-mutations positive advanced non-small cell lung cancer (NSCLC). This is a multicenter prospective biomarker study to investigate the usefulness of non-invasive liquid biopsy in the treatment of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and explore the molecular mechanism of acquired-resistance against afatinib (UMIN 000013806).

Methods

Eligible patients (pt.) had histologically and cytologically confirmed stage IIIB/IV adenocarcinoma of the lung with activating EGFR mutation. Afatinib was taken orally once daily at 40 mg/day. Plasma samples were collected upon before and during (4 and 24 weeks after initiation of treatment) afatinib treatment and disease progression. Plasma DNA (cfDNA) was analyzed using Scorpion-ARMS (ARMS), digital PCR (dPCR) and next generation sequencing (NGS).

Results

A total of 35 EGFR -mutation positive NSCLC pt. were enrolled from 10 institutions between May to Nov 2014. Twenty one pt. harbored a deletion in exon 19 and fourteen pt. had an L858R missense mutation in exon 21. Twenty seven (77.1%) of the 35 pt. had an objective response. CfDNA obtained from 32 pt. has been analyzed by ARMS, dPCR and NGS. Serial cfDNA up to 24 weeks has been monitored by dPCR and NGS. EGFR activating mutations in cfDNA obtained from pre-treatment plasma were identified in 84.3% (27/32), 75.0% (24/32) and 59.4% (18/32) by dPCR, NGS and ARMS, respectively. In 19 of 27 pt., active mutations turned to be undetectable by dPCR in cfDNA obtained at 4 weeks. As of Jul 2015, all of them have not experienced PD yet. In 18 of 24 pt., mutation frequency of active mutations in cfDNA calculated by NGS significantly decreased in 4 weeks and turned to be zero in 24 weeks.

Conclusions

EGFR activating mutations in plasma samples were frequently detected by dPCR or NGS. There is a possibility that evaluation of activating mutation levels in cfDNA is useful for estimating the efficacy of afatinib.

Clinical trial identification

UMIN 000013806

Disclosure

K. Nosaki: speaker's bureau; Nippon Boehringer Ingelheim Co., Ltd. K. Hotta: Taiho Pharmaceutical, Eli Lilly Japan, Daiichi Sankyo Company, Phizer Japan, Nippon Kayaku, Boehringer Ingelheim, Chugai Pharmaceutical, AstraZeneca, Sanofi, MSD. T. Kurata: Eli Lilly Japan, Phizer Japan, Chugai Pharmaceutical, AstraZeneca. K. Goto: Nippon Boehringer Ingelheim Co., Ltd (clinical trial grants and lectures)

Y. Nakanishi: Boehringer Ingelheim (lectures). I. Okamoto: Boehringer Ingelheim. All other authors have declared no conflicts of interest.